<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">{C-J} Chiu</style></author><author><style face="normal" font="default" size="100%">R Klein</style></author><author><style face="normal" font="default" size="100%">R C Milton</style></author><author><style face="normal" font="default" size="100%">G Gensler</style></author><author><style face="normal" font="default" size="100%">Allen Taylor</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Does eating particular diets alter the risk of age-related macular degeneration in users of the {Age-Related} Eye Disease Study supplements?</style></title><secondary-title><style face="normal" font="default" size="100%">The British Journal of Ophthalmology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">diet</style></keyword><keyword><style  face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Docosahexaenoic Acids</style></keyword><keyword><style  face="normal" font="default" size="100%">Eicosapentaenoic Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">glycemic index</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Macular Degeneration</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Reducing</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/19508997</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">93</style></volume><pages><style face="normal" font="default" size="100%">1241–1246</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">{BACKGROUND} Recent information suggests that the {Age-Related} Eye Disease Study {(AREDS)} supplement, enhanced intake of docosahexaenoic acid {(DHA)} and eicosapentaenoic acid {(EPA),} and reducing dietary glycaemic index {(dGI)} are protective against advanced age-related macular degeneration {(AMD).} {METHODS} Dietary information was collected at baseline, and fundus photograph grades were obtained during the 8-year trial period from 2924 eligible {AREDS} {AMD} trial participants. Using the eye as the unit of analysis and multifailure Cox proportional-hazards regression, the risk of {AMD} progression was related to dietary intake in the four arms of the trial. {RESULTS} Independent of {AREDS} supplementation, higher intakes of {DHA} ({\textgreater} or =64.0 vs {\textless}26.0 mg/day) (hazard ratio {(HR)} = 0.73, 95% confidence interval {(CI),} 0.57 to 0.94), {EPA} ({\textgreater} or =42.3 vs {\textless}12.7 mg/day) {(HR} = 0.74, 95% {CI} 0.59 to 0.94), and lower {dGI} {(dGI,} {\textless}75.2 vs {\textgreater} or =81.5) {(HR} = 0.76, 95% {CI} 0.60 to 0.96) were associated with a lower risk for progression to advanced {AMD.} Participants consuming a lower {dGI} and higher {DHA} or {EPA} had the lowest risk (p value for synergistic interaction {\textless}0.001). Only participants in the &quot;placebo&quot; (p value for antagonistic interaction = 0.006) benefited from a higher {DHA} intake against early {AMD} progression {(HR} = 0.58, 95% {CI} 0.37 to 0.92; P(trend) = 0.01). {CONCLUSIONS} The findings show an association of consuming a diet rich in {DHA} with a lower progression of early {AMD.} In addition to the {AREDS} supplement, a lower {dGI} with higher intakes of {DHA} and {EPA} was associated with a reduced progression to advanced {AMD.} Trial registration number: {NCT00000145.}</style></abstract><notes><style face="normal" font="default" size="100%">{PMID:} 19508997</style></notes></record></records></xml>